Evaluation of the proper dosage of lapatinib and its safety in dogs
Lapatinib is a low-molecular-weight agent targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It is one of the antitumor agents used against advanced breast cancer in human. We intended to apply it against canine mammary gland tumors (cMGTs). To...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tokyo Metropolitan Institute of Medical Science
2020
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/88878/1/DOG.pdf |
| _version_ | 1825936585838821376 |
|---|---|
| author | Tanaka, Yuiko Watanabe, Manabu Saeki, Kohei Ong, Siew Mei Yoshitake, Ryohei Imamura, Shohei Nishimura, Ryohei Sugano, Sumio Nakagawa, Takayuki |
| author_facet | Tanaka, Yuiko Watanabe, Manabu Saeki, Kohei Ong, Siew Mei Yoshitake, Ryohei Imamura, Shohei Nishimura, Ryohei Sugano, Sumio Nakagawa, Takayuki |
| author_sort | Tanaka, Yuiko |
| collection | UPM |
| description | Lapatinib is a low-molecular-weight agent targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It is one of the antitumor agents used against advanced breast cancer in human. We intended to apply it against canine mammary gland tumors (cMGTs). To this end, we evaluated the tolerated dosage and the side effects of lapatinib in healthy dogs. In this study, we conducted a dose-escalation toxicity test starting from 30 mg/kg to determine the maximum tolerated dose. Grade 3 toxicity, which was apparent as weight loss, was observed at the dose of 40 mg/kg/day. We then performed a long-term administration test and found that the dose of 35 mg/kg/day was well-tolerated within 7 weeks but caused grade 3 hepatic toxicity by the eighth week. In conclusion, our findings reveal that the dose of 35 mg/kg/day administered for no more than 8 weeks is fairly safe for use in healthy dogs. This dose is higher than the recommended dose for humans; thus, further studies evaluating the effective dose against canine tumors are needed. |
| first_indexed | 2024-03-06T10:46:31Z |
| format | Article |
| id | upm.eprints-88878 |
| institution | Universiti Putra Malaysia |
| language | English |
| last_indexed | 2024-03-06T10:46:31Z |
| publishDate | 2020 |
| publisher | Tokyo Metropolitan Institute of Medical Science |
| record_format | dspace |
| spelling | upm.eprints-888782021-10-05T00:17:08Z http://psasir.upm.edu.my/id/eprint/88878/ Evaluation of the proper dosage of lapatinib and its safety in dogs Tanaka, Yuiko Watanabe, Manabu Saeki, Kohei Ong, Siew Mei Yoshitake, Ryohei Imamura, Shohei Nishimura, Ryohei Sugano, Sumio Nakagawa, Takayuki Lapatinib is a low-molecular-weight agent targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It is one of the antitumor agents used against advanced breast cancer in human. We intended to apply it against canine mammary gland tumors (cMGTs). To this end, we evaluated the tolerated dosage and the side effects of lapatinib in healthy dogs. In this study, we conducted a dose-escalation toxicity test starting from 30 mg/kg to determine the maximum tolerated dose. Grade 3 toxicity, which was apparent as weight loss, was observed at the dose of 40 mg/kg/day. We then performed a long-term administration test and found that the dose of 35 mg/kg/day was well-tolerated within 7 weeks but caused grade 3 hepatic toxicity by the eighth week. In conclusion, our findings reveal that the dose of 35 mg/kg/day administered for no more than 8 weeks is fairly safe for use in healthy dogs. This dose is higher than the recommended dose for humans; thus, further studies evaluating the effective dose against canine tumors are needed. Tokyo Metropolitan Institute of Medical Science 2020 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/88878/1/DOG.pdf Tanaka, Yuiko and Watanabe, Manabu and Saeki, Kohei and Ong, Siew Mei and Yoshitake, Ryohei and Imamura, Shohei and Nishimura, Ryohei and Sugano, Sumio and Nakagawa, Takayuki (2020) Evaluation of the proper dosage of lapatinib and its safety in dogs. Translational and Regulatory Sciences, 2 (3). 68 - 71. ISSN 2434-4974 https://www.jstage.jst.go.jp/article/trs/2/3/2_2020-013/_html/-char/en 10.33611/trs.2020-013 |
| spellingShingle | Tanaka, Yuiko Watanabe, Manabu Saeki, Kohei Ong, Siew Mei Yoshitake, Ryohei Imamura, Shohei Nishimura, Ryohei Sugano, Sumio Nakagawa, Takayuki Evaluation of the proper dosage of lapatinib and its safety in dogs |
| title | Evaluation of the proper dosage of lapatinib and its safety in dogs |
| title_full | Evaluation of the proper dosage of lapatinib and its safety in dogs |
| title_fullStr | Evaluation of the proper dosage of lapatinib and its safety in dogs |
| title_full_unstemmed | Evaluation of the proper dosage of lapatinib and its safety in dogs |
| title_short | Evaluation of the proper dosage of lapatinib and its safety in dogs |
| title_sort | evaluation of the proper dosage of lapatinib and its safety in dogs |
| url | http://psasir.upm.edu.my/id/eprint/88878/1/DOG.pdf |
| work_keys_str_mv | AT tanakayuiko evaluationoftheproperdosageoflapatinibanditssafetyindogs AT watanabemanabu evaluationoftheproperdosageoflapatinibanditssafetyindogs AT saekikohei evaluationoftheproperdosageoflapatinibanditssafetyindogs AT ongsiewmei evaluationoftheproperdosageoflapatinibanditssafetyindogs AT yoshitakeryohei evaluationoftheproperdosageoflapatinibanditssafetyindogs AT imamurashohei evaluationoftheproperdosageoflapatinibanditssafetyindogs AT nishimuraryohei evaluationoftheproperdosageoflapatinibanditssafetyindogs AT suganosumio evaluationoftheproperdosageoflapatinibanditssafetyindogs AT nakagawatakayuki evaluationoftheproperdosageoflapatinibanditssafetyindogs |